Le Lézard
Classified in: Health
Subjects: RCL, CFG

Information Update - Certain hand sanitizers recalled because they may pose health risks


OTTAWA, ON, April 7, 2021 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers are being recalled because they may pose health risks. For more information, including what Canadians should do, visit the online safety alert.

Health Canada maintains this list of hand sanitizers that may pose health risks, so that Canadians can easily identify products they may have purchased and take appropriate action. Canadians are encouraged to check it regularly for updates.

Product

Reason for recall

Company

NPN or DIN

Lot Number(s)

Expiry Date

Aerochem Liquid Hand Cleaner 70% Alcohol

Not authorized for sale in Canada; contains unacceptable ingredient, ethyl acetate

Walter Surface Technologies Inc.

Unlicensed (no NPN or DIN on the label)

200342480

200342485

200342486

200342487

200342488

200342489

200342491

200342492

200342497

200442587

Not printed on the label

Gigi's Goodbye Germs Hand Sanitizer

Not authorized for sale in Canada; insufficient quality oversight of the product

Simply At Home Inc.

80101167

BB/MA 02/JN/2025

BB/MA 03/JN/2025

June 2025

JP Wiser's Distillery

Contains unacceptable ingredient, ethyl acetate

Hiram Walker & Sons Limited

80098173

200324-133735

Not printed on the label

Premium Hand Gel Sanitizer

Contains unacceptable ingredient, ethyl acetate

Ambassador Oil and Gas (current product license holder is Sunbee Environmental Solutions)

80098388

0420-01

0420-02

0420-03

April 2021

Premium Hand Sanitizer

Contains unacceptable ingredient, ethyl acetate

Ambassador Oil and Gas (current product license holder is Sunbee Environmental Solutions)

80098358

0420-04

0420-05

April 2021

Safe-Guard Product Canada Hand Sanitizer

Not authorized for sale in Canada; contains unacceptable ingredient, methanol

St. Joseph Communications

Unlicensed (no NPN or DIN on the label)

2020/05/11

May 2023

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP agilon health, inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm (AGL)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

More news about Health...


News published on and distributed by: